<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670809</url>
  </required_header>
  <id_info>
    <org_study_id>NJYK-LVDP-III</org_study_id>
    <nct_id>NCT04670809</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies</brief_title>
  <official_title>A Randomized, Single Blind, Positive Parallel Controlled, Multicenter, Phase III Clinical Trial of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergencies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Yoko Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Yoko Biomedical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the efficacy and safety of clevidipine for&#xD;
      treating Hypertensive emergencies（defined as systolic blood pressure &gt;180 mmHg and/or&#xD;
      diastolic blood pressure &gt;120 mmHg, accompanied by acute organ damage）.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target reaching rate within 30 min</measure>
    <time_frame>30 min</time_frame>
    <description>Proportion of subjects whose systolic blood pressure dropped to the target range (decrease ≥ 15% and ≤ 25% from baseline) in the first 30 minutes of administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean time of target reaching</measure>
    <time_frame>Procedure (whole infusion duration)</time_frame>
    <description>Mean time for subjects to reach target systolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful conversion to oral antihypertensive drugs</measure>
    <time_frame>6 hours after intravenous administration</time_frame>
    <description>Proportion of subjects who successfully converted to oral antihypertensive drugs within 6 hours after intravenous administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Hypertensive Emergency</condition>
  <arm_group>
    <arm_group_label>Clevidipine Butyrate Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ncardipine Hydrochloride Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevidipine Butyrate Injection</intervention_name>
    <description>Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.</description>
    <arm_group_label>Clevidipine Butyrate Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ncardipine Hydrochloride Injection</intervention_name>
    <description>Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.</description>
    <arm_group_label>Ncardipine Hydrochloride Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 75, regardless of gender.&#xD;
&#xD;
          2. Blood pressure increased seriously in a short time, systolic blood pressure (SBP) &gt;&#xD;
             180 mmHg and (or) diastolic blood pressure (DBP) &gt; 120 mmHg (measured at an interval&#xD;
             of 5 minutes, both blood pressure values should be &gt; 180 / 120 mmHg), accompanied with&#xD;
             progressive target organ damages as below or evidences of other target organ damage&#xD;
             can be confirmed:&#xD;
&#xD;
               -  Hypertensive encephalopathy: headache, dizziness, irritability, nausea, vomiting,&#xD;
                  blurred vision and other symptoms;&#xD;
&#xD;
               -  Acute left heart failure: dyspnea, pulmonary rales, edema and other symptoms;&#xD;
&#xD;
               -  Unstable angina pectoris: ischemic chest pain with ST-T dynamic changes. Patients&#xD;
                  with SBP ≥ 220mmhg and / or DBP ≥ 140mmHg should be considered as hypertensive&#xD;
                  emergency;&#xD;
&#xD;
          3. The legal representative and / or patient agree to participate in this clinical trial&#xD;
             and sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with arterial dissection, acute hemorrhagic or ischemic stroke, and acute&#xD;
             coronary syndrome in urgent need of surgical or emergency intervention;&#xD;
&#xD;
          2. Patients with severe aortic stenosis or severe mitral stenosis;&#xD;
&#xD;
          3. Patients with obstructive hypertrophic cardiomyopathy;&#xD;
&#xD;
          4. Patients who have used other intravenous antihypertensive drugs within 2 hours before&#xD;
             entering this study;&#xD;
&#xD;
          5. Patients known to be intolerant or allergic to calcium channel blockers, or allergic&#xD;
             to test drug ingredients, or allergic to soy / soy products or egg / egg products;&#xD;
&#xD;
          6. Patients with lipid metabolism defects, such as pathological hyperlipidemia, lipid&#xD;
             nephropathy, or acute pancreatitis with hyperlipidemia;&#xD;
&#xD;
          7. Combined with other serious organ injury or serious complications which may affect the&#xD;
             life of the subjects;&#xD;
&#xD;
          8. Patients with a history of mental illness;&#xD;
&#xD;
          9. Patients with known history of alcohol / drug abuse;&#xD;
&#xD;
         10. Those who have participated in other clinical trials and used test drugs 3 months&#xD;
             before the trial;&#xD;
&#xD;
         11. Pregnant and lactating women;&#xD;
&#xD;
         12. Researchers do not consider it appropriate to participate in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yiran Ge</last_name>
    <phone>15298359892</phone>
    <email>geyiran@yoko-bio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo, professor</last_name>
      <phone>13910039007</phone>
      <email>shubinguo@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Malignant</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clevidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

